Identity and synonyms
Separate precursor, mature isoform and AAV construct; no single vendor sequence assumed.
Synonyms: FS344 · FST (isoforms differ)
Protein or biologic · Protein or protein analogue
Detailed molecular class: Protein / biologic
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Binds activin/myostatin-related ligands.
Evidence and critical reading
Reported scientific and empirical uses
Reported muscle and performance
Offered as FST344 for myostatin inhibition; variants and delivery form matter.
Human evidence
Six-person Becker muscular dystrophy gene-therapy study is not evidence for injected vendor protein in bodybuilding.
Preclinical evidence
Gene delivery, mature protein and isoforms have different exposure biology.
Critical reading and limitations
A six-patient study used an AAV FS344 vector, not vial protein. Viral genomes cannot be converted to product micrograms.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
50–300 mcg · Total daily amount
- Frequency
- Once/day
- Duration
- 2–4 weeks
- Route
- Subcutaneous
- Context
- Commercial protein; the human AAV-FS344 trial was another intervention.
- Presentation
- Not stated on selected page.
- Interpretation
- Regimen attributed to handbook, without clinical validation for this use; not a recommendation.
manual07 · Page 37 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Gene-therapy observations cannot certify protein-product safety; off-target endocrine effects and long-term risks require study.
Activin-ligand interaction and reproductive uncertainty require specific research rather than a generic cycle.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID25322757 · Early gene-therapy study
Becker muscular dystrophy.
AAV-FS344 gene therapy.
Exploratory functional signals in a small study.
Genetic intervention differs from commercial protein; not a trial of the handbook’s mcg/day regimen.
n = 6
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Follistatin · 15 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07804719 · Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's SyndromeRegistry status: Active, not recruitingLast update posted: September 24, 2026Query verification: October 16, 2026
NCT07285629 · Safety and Efficacy of Klotho and Follistatin Gene TherapyRegistry status: CompletedLast update posted: August 27, 2026Query verification: October 16, 2026
NCT07443826 · CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene TherapyRegistry status: RecruitingLast update posted: July 13, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID25322757
A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.
Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK.
October 16, 2026
- R40
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026